false
Catalog
Symposium: Addressing the Emerging Drug Threat of ...
Addressing the Emerging Drug Threat of Fentanyl Ad ...
Addressing the Emerging Drug Threat of Fentanyl Adulterated or Associated with Xylazine via Harm Reduction and Clinical Innovation
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this final symposium at the AAAP conference, the discussion centered around the growing threat of fentanyl adulterated with xylazine, and how emerging drug trends are being tackled through harm reduction and clinical innovations. The symposium was chaired by Dr. Adam Gordon and included experts from various institutions. Key speakers included Grant Baldwin from the CDC, Dr. Joseph Liberto from the VA, and Elizabeth Oliva from the VA Center for Innovation and Implementation.<br /><br />Dr. Baldwin presented recent data showing a decrease in U.S. overdose deaths, attributing it to various interventions, including wider naloxone availability and transitions in drug use behaviors from injection to smoking. He emphasized the increasing presence of xylazine in the drug supply, and its identification as an emerging drug threat owing to its severe health implications.<br /><br />Dr. Liberto and Dr. Oliva highlighted the VA's strategies in addressing substance use disorders (SUD) among veterans. They emphasized the expansion of evidence-based treatments, the integration of harm reduction measures like naloxone distribution, and innovation in care models to enhance treatment pathways. Notably, the VA's initiatives have expanded beyond traditional SUD specialty care to include primary care, mental health, and pain clinics, fostering better management of emerging drug threats like xylazine.<br /><br />Dr. Gordon concluded by stressing the strategic shift towards inclusive harm reduction strategies and collaborative care models, which have successfully increased veteran access to medication treatment and integrated care management practices, especially crucial in addressing complex cases of xylosine exposure. The symposium underscored the importance of adaptive health systems and informed community engagement to mitigate the risks posed by evolving drug challenges.
Keywords
Veterans Affairs
opioid crisis
fentanyl
xylosine
overdose rates
harm reduction
naloxone distribution
substance use disorders
holistic care
syringe service programs
addiction treatment
veteran health
AAAP conference
xylazine
emerging drug trends
clinical innovations
Dr. Adam Gordon
Grant Baldwin
CDC
Dr. Joseph Liberto
VA
Elizabeth Oliva
naloxone
veterans
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.
400 Massasoit Avenue
Suite 108
East Providence, RI 02914
cmecpd@aaap.org
Privacy
About
Advocacy
Membership
Fellowship
Education and Resources
Training Events
×
Please select your language
1
English